InspireMD, Inc. NSPR
Medical/Dental Instruments · data as of November 13, 2026
InspireMD, Inc. (NSPR) is a healthcare company listed in the US with a market value of about $30M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$40M, a net margin of -376.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 29% a year, a 5-year average ROIC of -57%.
About InspireMD
InspireMD is listed in the US and classified in medical/dental instruments. Revenue went from $3M in 2014 to $9M in 2025, growth of about 11.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 717% over three years (dilution for shareholders). It spends 167% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11M | $9M | $7M | $6M | $5M | $4M | $2M | $4M | $4M | $3M | $2M |
| Net income | -$40M | -$49M | -$32M | -$20M | -$18M | -$15M | -$11M | -$10M | -$7M | -$8M | -$8M |
| Free cash flow | — | -$37M | -$23M | -$17M | -$16M | -$14M | -$9M | -$10M | -$8M | -$8M | -$8M |
| EPS (diluted) | $-0.49 | $-0.76 | $-0.76 | $-0.82 | $-2.35 | $-2.03 | $-6.97 | $-72.00 | $-250.05 | $-26235.00 | $-155789.99 |
| Net margin | -376.6% | -543.3% | -456.6% | -321.0% | -357.6% | -331.9% | -424.3% | -269.8% | -201.1% | -305.6% | -446.7% |
| ROIC | — | -67.0% | -68.9% | -39.9% | -77.8% | -33.5% | -62.3% | -128.5% | -68.6% | -238.5% | -89.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $3.33, 418% above the current price; targets range from $3.00 to $4.00; the consensus rating is “Buy”; expected EPS is $-0.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does InspireMD pay a dividend?
Not currently.
Is InspireMD a good stock to buy?
We do not give buy or sell advice. InspireMD scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.